Chugai files lawsuit to protect its Herceptin

11 September 2017

Japan’s Chugai Pharmaceutical (TYO: 4519) saw its shares gain 2.15% to 4,515 yen, after it revealed legislation to protect one of its top-selling drugs from biosimilar competition.

Chugai, which is majority owned by Swiss pharma giant Roche (ROG: SIX), has filed a lawsuit to the Tokyo District Court and has also filed a petition for provisional disposition order, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin (trastuzumab) Injection 60 and 150, against Nippon Kayaku (TYO: 4272) the applicant for approval of the biosimilar of Herceptin Injection, citing such party’s infringement of the application patent owned by Genentech, a wholly-owned subsidiary, as the ground.

Genentech is a patent holder and Chugai is the exclusive licensee of Herceptin Injection. Both are the co-plaintiff of the lawsuit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK